Statins and muscle pain: what to do about it

How common muscle symptoms really are

In everyday practice muscle aching is the complaint most frequently linked to statins, and it is the leading reason patients stop taking them. That much is not in dispute.

What is more surprising is what happens when the question is tested blind. Randomised studies in which patients alternated between a statin and an identical dummy tablet without knowing which they were taking, including the SAMSON study published in 2020 and the StatinWISE trial published in 2021, found that the great majority of the symptom burden recorded during statin months was also recorded during placebo months. Patients felt genuinely unwell in both. The symptoms were real. The attribution to the statin frequently was not.

That finding should be read carefully rather than dismissively. It does not mean nobody gets muscle symptoms from statins. A minority clearly do, and a very small number develop genuine muscle injury. It means that the question of whether this statin, at this dose, is causing this ache is answerable and worth answering, instead of being settled by guesswork in the patient's kitchen.

The method for answering it is straightforward, and it belongs to your GP rather than to a website.

What statin muscle symptoms typically feel like

The usual description is a symmetrical, dull aching or heaviness in the large muscle groups, most often the thighs, hips, shoulders, upper arms and calves. It tends to affect both sides rather than one. It often appears within weeks of starting or of a dose increase, and settles within weeks of stopping.

Some patients report weakness rather than pain, or cramp, or difficulty with stairs and getting up from a chair.

Several patterns argue against the statin being the cause: pain confined to one joint, pain that started long before the statin and has not changed, pain that is worse first thing and eases with movement in the way inflammatory joint disease behaves, and pain following an obvious mechanical trigger such as unaccustomed exercise or a fall.

The timing is the most useful clue you can bring to an appointment. When did the tablet start, when did the ache start, did anything else change in the same period. Writing that timeline down before the appointment saves more consultation time than any test.

The symptoms that need urgent attention

Severe muscle pain or marked weakness together with dark, cola-coloured urine needs to be assessed urgently, because that combination can indicate significant muscle breakdown. Do not wait for the next routine appointment. Contact a GP or a GP out of hours service, and in an emergency call 112 or 999.

That picture is rare. It matters because it is the one presentation where stopping the tablet without waiting for advice is the right instinct, and where the priority is being seen rather than being reassured.

A second, also rare, situation is muscle weakness that persists or worsens after the statin has been stopped, which needs specialist assessment rather than simply trying a different statin.

Yellowing of the skin or eyes, severe abdominal pain, or a rash with blistering are unrelated to muscle but are reasons to seek medical advice about any medicine promptly.

Everything short of that is a routine conversation with your GP rather than an emergency, and the routine conversation is where the majority of cases are solved.

What a doctor checks before changing anything

Creatine kinase is the blood test that measures muscle breakdown, and it is the first thing checked when muscle symptoms are reported. A normal result in someone with aching muscles is common and is informative in itself, because it makes serious muscle injury unlikely and opens the door to a structured trial of dose change or switching.

Thyroid function comes next, because an underactive thyroid produces muscle aching and fatigue that mimics statin myalgia exactly, and because untreated hypothyroidism also increases the risk of genuine statin muscle problems. It is one of the most commonly missed explanations.

Kidney function and liver tests are usually included, both as safety checks and because reduced kidney function raises statin levels.

Vitamin D is sometimes checked, since deficiency is associated with muscle aching, although the evidence that correcting it resolves statin-associated symptoms is not strong.

The medicines list gets reviewed at the same time, and that review often finds the answer. Alcohol intake, recent unaccustomed exercise and any new physical work in the same period get asked about for the same reason.

Interactions and other causes that get missed

Statin levels in the blood are raised by a number of common medicines, and higher levels mean a higher chance of muscle problems.

Certain antibiotics, notably clarithromycin, and several antifungal medicines are classic examples. So are ciclosporin, some antiviral treatments, and fibrates, with gemfibrozil the one most associated with muscle problems in combination. Amiodarone and verapamil interact with particular statins. Grapefruit juice in quantity raises the levels of some statins and not others.

The important point is that these interactions are statin-specific. A combination that is a problem with one statin may be entirely acceptable with another, which is one of several reasons that switching statins is a real strategy rather than a placebo move.

This is also why the full list of what you take, including anything bought over the counter and any supplement, is worth bringing to the appointment. Patients routinely omit supplements from the list because they do not think of them as medicines.

A short course of an interacting antibiotic sometimes leads to the statin being paused for those days, which is a decision for the prescriber rather than a general rule.

What usually gets changed first

The standard approach is a structured sequence rather than a single decision.

Often the statin is paused for a defined period to see whether the symptoms actually settle. If they do not, the statin was not the cause and the search moves elsewhere, which is a useful result.

If they do settle, the same statin may be restarted at a lower dose, or a different statin tried. Statins differ in how they are handled by the body, and patients who cannot tolerate one frequently tolerate another without difficulty.

Less frequent dosing of a long-acting statin is used in some patients who cannot manage daily dosing.

Where no statin is tolerated at any dose, other lipid-lowering options exist. Ezetimibe is the usual next step and works differently, and there are further options in specialist care. They are not equivalent to a statin in terms of the evidence behind them, which is why they come after rather than instead.

All of these are prescribing decisions taken with knowledge of your cardiovascular risk, your cholesterol results and your other conditions. None of them is a reason to change what you take on your own.

Why stopping without review is the expensive option

A statin is prescribed to lower the chance of a heart attack or a stroke over years. That benefit is invisible day to day, which is exactly what makes silent discontinuation so easy. Nothing happens the week you stop, and nothing happens the month after.

What the research consistently shows is that patients who stop after attributing symptoms to the statin very often tolerate a rechallenge, either with the same medicine at a lower dose or with a different one. Stopping permanently on the basis of an untested assumption gives up the benefit in exchange for a symptom that might well have persisted anyway.

There is also a documentation cost. Long gaps in treatment make future prescribing more cautious, because a prescriber reviewing a repeat request needs to know whether treatment is ongoing, at what dose and with what monitoring.

The reasonable position is neither to suffer in silence nor to stop in silence. Report the symptom, get the bloods, and let the sequence above run. Most people end up on a statin they can live with.

Keeping the prescription going while you sort the symptom

If your treatment is settled and it is the prescription rather than the medicine that has run out, that is a different problem and a smaller one.

MEDINOW runs a repeat prescription assessment at 19.90 euro for treatment you are already established on. You complete a written medical questionnaire covering the medicine, the dose, how long you have taken it, your recent monitoring and anything that has changed. Lek. Damian Wojno reads it in his own time and either issues a prescription document sent to you by email as a PDF laid out to the Annex to Directive 2012/52/EU, or declines and explains why. There is no video consultation, no telephone appointment and no live chat.

For a statin, expect to be asked about recent lipid results, kidney and liver tests, and any muscle symptoms. If your monitoring is out of date, the doctor may ask for it before issuing anything, and that request is the point of the review rather than an obstacle to it.

The fee covers the medical assessment and not the issuing of a document. If the doctor declines on medical grounds, the fee is refunded. If the doctor asks for documentation and you do not send it, the assessment counts as carried out and the fee is not refunded.

What this service is not is a way to resolve an active muscle symptom. New or worsening muscle pain belongs with a doctor who can examine you and arrange bloods, which means your GP.

Who wrote this page

Written by the MEDINOW editorial team and reviewed by lek. Damian Wojno, a doctor registered in Poland, PWZ no. 3211301. He is not on the Irish Medical Council register. Reviewed on 29 August 2026.

This is general information about a common problem with a common class of medicine. It is not personal medical advice, it does not tell you whether your statin is causing your symptoms, and it is not a reason to change or stop any treatment on your own.

The blinded trial findings referred to here are the SAMSON study published in the New England Journal of Medicine in 2020 and the StatinWISE trial published in the BMJ in 2021. Product-specific detail such as interactions and dosing was left to the summary of product characteristics for each individual statin on medicines.ie rather than summarised into a single sentence here, because those details differ between statins and that difference is the whole point of the section on switching.